Cahn Medical Ventures invests for the long term in early-stage medical
technology companies, filling the significant gap that exists between angel
investing and institutional venture capital investing rounds.
Cylex achieves near tripling of Medicare reimbursement READ MORE
CytoSorbents obtains CE mark for CytoSorb™ and commences sales program READ MORE
TyRx anticipates FDA approval of significant product upgrade by mid year READ MORE
